Live Coverage from the GU Cancers ...
Check out our coverage of the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA
Combo Superior for Advanced RCC
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Improving Dialysis for Undocumented Immigrants
Many are calling for standard dialysis coverage for undocumented immigrants with end-stage renal disease.
Abiraterone, Prednisone Efficacious in mCNPC
At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.
Cancer Death Risk Up in Dialysis ...
Dialysis patients were more likely than transplant recipients to die from pre-existing cancers, whereas transplant recipients were more likely to die from de novo cancers.
Darolutamide Ups Survival in CRPC
Median metastasis-free survival was longer with darolutamide than with placebo: 40.4 vs 18.4 months.
Email Precautions Can Prevent Breaches
Staff at medical practices should be taught to recognize suspicious email messages
When Patients Refuse Treatment
Find Jobs
Check out Renal & Urology News' job board
ZERBAXA (ceftolozane and tazobactam)
For complicated UTIs, including pyelonephritis, and intra-abdominal infections.
TRIFERIC® (ferric pyrophosphate citrate) solution
For iron replacement in adults with chronic kidney disease on hemodialysis.
Avycaz™ (ceftazidime-avibactam)
For treatment of complicated intra-abdominal infections and urinary tract infections.
Cartoons
Online Poll
Jan-Feb Digital Issue
CME Spotlight
Evolving Strategies in the Diagnosis and Management of ADPKD
CME|CE
1.50 Credits
Renal and Urology News Articles
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
- Obesity Linked With Improved Survival in mCRPC
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Prednisone to Blame for ERA 223 Trial Failure?
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Study Supports Once-Daily Plazomicin Use for Complicated UTIs
- Prednisone to Blame for ERA 223 Trial Failure?
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Anemia
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetes
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Hemodialysis
- Hyperkalemia
- Hyperphosphatemia
- Hypertension
- Hyperuricemia
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
- Transplantation